Skip to main content
. Author manuscript; available in PMC: 2021 Dec 1.
Published in final edited form as: Breast Cancer Res Treat. 2020 Sep 22;184(3):927–935. doi: 10.1007/s10549-020-05903-z

Table 1.

Baseline patient characteristics

Variable n (%)
Age
 < 50 303 (58.5)
 ≥ 50 215 (41.5)
Menopausal status
 Pre-menopausal 221 (42.7)
 Peri/post-menopausal 297 (57.3)
Height (cm)
 Mean ± SD 162.0 ± 6.9
 Median (IQR) 162.0 (157, 166.3)
Weight (kg)
 Mean ± SD 66.8 ± 13.5
 Median (IQR) 64.1 (57.8, 73.0)
Body mass index (kg/m2)
 ≤ 25 283 (54.6)
 25–30 150 (29.0)
 > 30 85 (16.4)
Hormone receptor expression
 Either ER or PR positive/equivocal 370 (71.4)
 Both ER and PR negative 75 (14.5)
 Missing 73 (14.1)
Tumour stage
 T1 290 (56.0)
 T2 167 (32.2)
 T3 25 (4.8)
 TX 36 (7.0)
Nodal status
 Negative 362 (69.9)
 Positive 156 (30.1)
Tumour grade
 1 77 (14.9)
 2 216 (41.7)
 3 181 (34.9)
 Missing 44 (8.5)
Surgery type
 Mastectomy 117 (22.6)
 Lumpectomy 401 (77.4)
Adjuvant chemotherapy
 No 315 (60.8)
 Yes 203 (39.2)
Adjuvant hormonal therapy
 No 318 (61.4)
 Yes 200 (38.6)
Adjuvant radiation
 No 138 (26.6)
 Yes 380 (73.4)